GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agentix Corp (OTCPK:AGTX) » Definitions » Cash Flow from Financing

Agentix (Agentix) Cash Flow from Financing : $0.05 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Agentix Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Agentix paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.05 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Agentix earned $0.05 Mil on financial activities for the three months ended in Dec. 2023.


Agentix Cash Flow from Financing Historical Data

The historical data trend for Agentix's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agentix Cash Flow from Financing Chart

Agentix Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Mar23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only 0.05 0.06 - 0.18 0.10

Agentix Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.05 -0.05 0.05

Agentix Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Agentix's Cash from Financing for the fiscal year that ended in Mar. 2023 is calculated as:

Agentix's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Agentix  (OTCPK:AGTX) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Agentix's issuance of stock for the three months ended in Dec. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Agentix's repurchase of stock for the three months ended in Dec. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Agentix's net issuance of debt for the three months ended in Dec. 2023 was $0.05 Mil. Agentix received $0.05 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Agentix's net issuance of preferred for the three months ended in Dec. 2023 was $0.00 Mil. Agentix paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Agentix's cash flow for dividends for the three months ended in Dec. 2023 was $0.00 Mil. Agentix received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Agentix's other financing for the three months ended in Dec. 2023 was $0.00 Mil. Agentix received $0.00 Mil on other financial activities.


Agentix Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Agentix's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Agentix (Agentix) Business Description

Traded in Other Exchanges
N/A
Address
32932 Pacific Coast Highway, Suite 14-254, Dana Point, CA, USA, 92629
Agentix Corp is a biotechnology company. It is engaged in the development and commercialization of novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. Its principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and continue to drive innovations in the endocannabinoid space.
Executives
Thomas E Puzzo 10 percent owner 4216 NE 70TH STREET, SEATTLE WA 98115
Michael Winterhalter director, 10 percent owner, officer: President, CEO, CFO, Treasurer 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Grays Peak Ventures Llc 10 percent owner 320 PARK AVE, NEW YORK NY 10022
Scott B Stevens director, officer: President and Director 9701 WILSHIRE BLVD., SUITE 1000, BEVERLY HILLS CA 90212
Robert K Whalen director, officer: Secretary and Treasurer 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Scott Thomas director 14 MONARCH BEACH PLAZA, SUITE 254, MONARCH BEACH CA 92629
Robert Drust director 14 MONARCH BEACH PLAZA, SUITE 254, MONARCH BEACH CA 92629
Eric Krogius director, 10 percent owner 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Bao Dong Han 10 percent owner 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629

Agentix (Agentix) Headlines

No Headlines